Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 3/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6921842 | 0.82 | CHRM5 (0.36) | SLC6A2SLC6A4OPRD1CHRM5CHRM3 | |
| SCHEMBL6921835 | 0.82 | CHRM5 (0.36) | SLC6A2SLC6A4OPRD1CHRM5CHRM3 | |
| SCHEMBL19159745 | 0.78 | SLC6A2 (0.32) | SLC6A2SLC6A4OPRD1CHRM5CHRM3 | |
| SCHEMBL11120070 | 0.78 | OPRD1 (0.37) | SLC6A2SLC6A4OPRD1CHRM5CHRM3 | |
| SCHEMBL11114473 | 0.78 | SMN1; SMN2 (0.36) | SLC6A2SLC6A4OPRD1CHRM5CHRM3 | |
| SCHEMBL14748115 | 0.78 | SMN1; SMN2 (0.33) | SMN1; SMN2 | |
| SCHEMBL10284434 | 0.76 | SMN1; SMN2 (0.36) | SMN1; SMN2 | |
| SCHEMBL2551138 | 0.76 | KDM4E (0.37) | SLC6A2SLC6A4OPRD1CHRM5CHRM3 | |
| SCHEMBL13419180 | 0.76 | KDM4E (0.37) | SLC6A2SLC6A4OPRD1CHRM5CHRM3 | |
| SCHEMBL3534793 | 0.76 | KDM4E (0.37) | SLC6A2SLC6A4OPRD1CHRM5CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2565193-A1 | Compositions and methods for inhibition of the JAK pathway | Rigel Pharmaceuticals, Inc. (US) | 2013-03-06 | — | — | EP | disclosed |
| WO-2012015972-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2012-02-02 | — | — | WO | disclosed |